At a glance
ClinicalIndex Comparison RecordN/ACompleted· 115 enrolled
Drug / intervention
Aprepitant +1 moredrug
Likely dose
Aprepitant 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind Comparison of Oral Aprepitant Alone vs Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting
In Brief
A clinical study evaluating Aprepitant and Scopolamine for Nausea and Vomiting. Completed, enrolled 115 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the incidence of nausea, vomiting, need for rescue medication, prolonged PACU time, and unplanned hospital admission in patients with high risk for post-operative nausea and vomiting (PONV) treated with oral aprepitant with or without transdermal scopolamine preoperatively.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedJul 2008
Primary CompletionMar 2010
TodayJul 2026
First PostedJul 16, 2008
Enrollment StartFeb 1, 2008
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 18.0 years ago
Interventions
Aprepitantdrug
Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
Scopolaminedrug
Scopolamine transdermal applied to skin behind the ear one hour prior to surgery